The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 657-664

  Hansen, Henrik H ^a   Jelsing, Jacob ^a   Hansen, Carl Frederik ^a   Hansen, Gitte ^a   Vrang, Niels ^a   Mark, Michael ^b   Klein, Thomas ^b   Mayoux, Eric ^b  

^a Gubra ApS   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; KI 67 ANTIGEN; LIRAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SGLT2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DRUG DOSE TITRATION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; METABOLISM; PHYSIOLOGY; RANDOMIZATION; ZUCKER RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSIDES; HOMEOSTASIS; INSULIN-SECRETING CELLS; MALE; RANDOM ALLOCATION; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84907291903     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213454     Document Type: Article

References (33)

1. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, and Saito A (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578-586.
2. Bailey CJ (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63-71.
3. Biederman JI, Vera E, Rankhaniya R, Hassett C, Giannico G, Yee J, and Cortes P (2005) Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes. Kidney Int 67:554-565.
4. Brand CL, Galsgaard ED, Tornehave D, Rømer J, Gotfredsen CF, Wassermann K, Knudsen LB, Vølund A, and Sturis J (2009) Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes Obes Metab 11:795-803.
5. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, and Isaji M (2009) Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609:148-154.
6. Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E, Woods J, Zhu Y, Shao Q, and Maruki-Uchida H, et al. (2012) Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55:1071-1080.
7. Ghosh RK, Ghosh SM, Chawla S, and Jasdanwala SA (2012) SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 52:457-463.
8. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, and Pakkenberg B, et al. (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96:857-881.
9. Gyte A, Pritchard LE, Jones HB, Brennand JC, and White A (2007) Reduced expression of the KATP channel subunit, Kir6.2, is associated with decreased expression of neuropeptide Y and agouti-related protein in the hypothalami of Zucker diabetic fatty rats. J Neuroendocrinol 19:941-951.
10. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439.
11. Kahn SE, Hull RL, and Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846.
12. Kern M, Kloting N, Mayoux E, Mark M, Klein T, and Bluher M (2012) The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin improves insulin sensitivity in db/db mice in a dose-dependent manner. 72nd Scientific Session of the American Diabetes Association; 2012 Jun 8-12; Philadelphia, PA. pp 1024-102P, American Diabetes Association, Alexandria, VA.
13. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, and Conway B, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7:e30555.
14. Luippold G, Klein T, Mark M, and Grempler R (2012) Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 14:601-607.
15. Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, and Poucher SM (2010) The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 12:1004-1012.
16. Margolis RN (1987) Hepatic glycogen synthase phosphatase and phosphorylase phosphatase activities are increased in obese (fa/fa) hyperinsulinemic Zucker rats: effects of glyburide administration. Life Sci 41:2615-2622.
17. Mine T, Miura K, Kitahara Y, Okano A, and Kawamori R (2002) Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharm Bull 25:1412-1416.
18. Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, and Jelsing J (2010) Stereological assessment of pancreatic beta-cell mass development in male Zucker diabetic fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat 217:624-630.
19. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, and Polonsky KS (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47: 358-364.
20. Pi-Sunyer FX (2009) The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med 121: 94-107.
21. Prentki M and Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812.
22. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, and Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-3434.
23. Rendell M (2004) The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64:1339-1358.
24. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, and Woerle HJ (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:1154-1160.
25. Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, and Dugi KA (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28: 213-219.
26. Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, and Stehno-Bittel L (2013) Long-term liraglutide treatment is associated with increased insulin content and secretion in b-cells, and a loss of a-cells in ZDF rats. Pharmacol Res 76:58-66.
27. Someya Y, Nakano R, Tahara A, Takasu T, Takeuchi A, Nagase I, Matsuyama-Yokono A, Hayakawa M, Sasamata M, and Miyata K, et al. (2009) Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure. Eur J Pharmacol 622:71-77.
28. Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. Am J Med 123:S3-S11.
29. Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, and Carr RD, et al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123-132.
30. Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, Eickelmann P, and Mark M (2012) Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 14:94-96.
31. Topp BG, Atkinson LL, and Finegood DT (2007) Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats. Am J Physiol Endocrinol Metab 293:E1730-E1735.
32. Tsuura Y, Ishida H, Okamoto Y, Tsuji K, Kurose T, Horie M, Imura H, Okada Y, and Seino Y (1992) Impaired glucose sensitivity of ATP-sensitive K+ channels in pancreatic beta-cells in streptozotocin-induced NIDDM rats. Diabetes 41:861-865.
33. Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Søeborg H, and Knudsen LB (2012) The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 303:E253-E264.